TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Neonc Technologies
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

NeOnc Technologies will host an investor conference call to present data updates from its ongoing Phase 1/2a NEO100-1 clinical trial, focusing on intranasal delivery of NEO100 for treating recurrent high-grade malignant glioma.

Insights
NTHI   positive

Company is presenting promising clinical trial data, hosting an investor conference, and demonstrating progress in brain cancer treatment research